Formulation of botulinum neurotoxin heavy chain fragments for vaccine development: mechanisms of adsorption to an aluminum-containing adjuvant

被引:9
作者
DePaz, RA
Henderson, I
Advant, SJ
机构
[1] Diosynth Biotechnol, Dept Pharmceut Sci & Stabil, Morrisville, NC 27560 USA
[2] DynPort Vaccine Co LLC, Frederick, MD 21702 USA
[3] AlphaVax Inc, Res Triangle Pk, NC 27709 USA
关键词
botulinum neurotoxin; botulism; aluminum adjuvants;
D O I
10.1016/j.vaccine.2005.03.028
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Heavy chain fragments of botulinum neurotoxin serotypes A and B are being developed as a bivalent vaccine for botulism. To potentiate the immune response, an aluminum containing adjuvant will be formulated with the two antigens. The adsorption mechanisms of each antigen to aluminum phosphate and aluminum hydroxide adjuvants were studied. The adsorption of the serotype A antigen to each adjuvant, and the serotype B antigen to aluminum phosphate adjuvant, is dependent on electrostatic attractive forces. The serotype A antigen is basic, and pretreatment with phosphate anions is required for favorable adsorption conditions to aluminum hydroxide adjuvant. In contrast, the serotype B antigen displays a high affinity to aluminum hydroxide adjuvant even when the two species possess the same charge. It is proposed that the serotype B antigen is adsorbed to aluminum hydroxide adjuvant by a ligand exchange mechanism. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4029 / 4035
页数:7
相关论文
共 31 条
[1]  
ACHARYA P, 2002, AAPS PHARM SCI
[2]   EFFECT OF PROTEIN ADSORPTION ON THE SURFACE-CHARGE CHARACTERISTICS OF ALUMINUM-CONTAINING ADJUVANTS [J].
ALSHAKHSHIR, R ;
REGNIER, F ;
WHITE, JL ;
HEM, SL .
VACCINE, 1994, 12 (05) :472-474
[3]   CONTRIBUTION OF ELECTROSTATIC AND HYDROPHOBIC INTERACTIONS TO THE ADSORPTION OF PROTEINS BY ALUMINUM-CONTAINING ADJUVANTS [J].
ALSHAKHSHIR, RH ;
REGNIER, FE ;
WHITE, JL ;
HEM, SL .
VACCINE, 1995, 13 (01) :41-44
[4]   Use of biophysical characterization in preformulation development of a heavy-chain fragment of botulinum serotype B: Evaluation of suitable purification process conditions [J].
Bedu-Addo, FK ;
Johnson, C ;
Jeyarajah, S ;
Henderson, I ;
Advant, SJ .
PHARMACEUTICAL RESEARCH, 2004, 21 (08) :1353-1361
[5]   Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate [J].
Byrne, MP ;
Smith, TJ ;
Montgomery, VA ;
Smith, LA .
INFECTION AND IMMUNITY, 1998, 66 (10) :4817-4822
[6]   Development of vaccines for prevention of botulism [J].
Byrne, MP ;
Smith, LA .
BIOCHIMIE, 2000, 82 (9-10) :955-966
[7]   THE IMPORTANCE OF SURFACE-CHARGE IN THE OPTIMIZATION OF ANTIGEN ADJUVANT INTERACTIONS [J].
CALLAHAN, PM ;
SHORTER, AL ;
HEM, SL .
PHARMACEUTICAL RESEARCH, 1991, 8 (07) :851-858
[8]  
Chang MF, 1997, PDA J PHARM SCI TECH, V51, P25
[9]   Degree of antigen adsorption in the vaccine or interstitial fluid and its effect on the antibody response in rabbits [J].
Chang, MF ;
Shi, Y ;
Nail, SL ;
HogenEsch, H ;
Adams, SB ;
White, JL ;
Hem, SL .
VACCINE, 2001, 19 (20-22) :2884-2889
[10]  
Cherington M, 1998, MUSCLE NERVE, V21, P701, DOI 10.1002/(SICI)1097-4598(199806)21:6<701::AID-MUS1>3.0.CO